GlassScriptPhysician profile
Dennis P Lewis
NPI 1780608190
$5,166.86
in general payments reported to CMS, 2019-2025
36 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $495 · 2020: $361 · 2021: $744 · 2022: $589 · 2023: $1,058 · 2024: $844 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,978.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $780.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $687.09 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $647.07 | 2021-2025 | |
| Novo Nordisk INC | $343.55 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $343.21 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $222.26 | 2021-2023 | Verquvo, Belsomra |
| Eisai INC. | $197.08 | 2020-2022 | |
| Amgen INC. | $178.75 | 2020-2025 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $175.51 | 2019-2024 | Trelegy Ellipta |
| Exact Sciences Corporation | $167.83 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.66 | 2019-2024 | Jardiance |
| Idorsia Pharmaceuticals US INC | $128.38 | 2023 | Quviviq |
| Supernus Pharmaceuticals, INC. | $109.36 | 2019-2020 | |
| Esperion Therapeutics, INC. | $103.02 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $93.13 | 2020-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $83.93 | 2022 | |
| Phathom Pharmaceuticals, INC. | $74.32 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $62.84 | 2021 | |
| Allergan, INC. | $56.72 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $54.83 | 2025 | |
| Genentech USA, INC. | $51.32 | 2019-2022 | |
| Corcept Therapeutics | $50.85 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $47.90 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $44.34 | 2021 | |
| Arbor Pharmaceuticals, INC. | $43.50 | 2019-2020 | |
| Amarin Pharma, INC. | $40.78 | 2020 | |
| Janssen Pharmaceuticals, INC | $38.06 | 2019-2023 | Xarelto |
| Sumitomo Pharma America, INC. | $28.98 | 2025 | Gemtesa |
| Lucid Diagnostics INC. | $27.14 | 2022 | |
| Upsher-Smith Laboratories LLC | $27.06 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $26.26 | 2025 | Rexulti |
| Gilead Sciences, INC. | $25.51 | 2023 | |
| Paratek Pharmaceuticals, INC. | $23.14 | 2025 | Nuzyra |
| Vertiflex, INC. | $17.63 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.69 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.